CPD Events

Interactive debate: IO/TKI combination therapy versus TKI monotherapy in first-line aRCC

31 Mar 2022

About the event

This is a debate meeting intended for UK HCPs to support their understanding of IO/TKI therapy in first-line treatment of advanced renal cell carcinoma (aRCC).

CPD Provider

Merck Serono LTD

Send an enquiry

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Merck Serono LTD

Merck Serono LTD

Merck is a global science and technology company with a passion for forward-thinking discoveries. We want to develop products and solutions for a better life. That's why we take a closer look at things, ask questions and think ahead. More than 52,000 employees in 66 countries work together with us on innovative solutions and the newest technologies in healthcare, life science and performance materials. From improving electronic devices with smarter materials to generating ultra pure water, testing the quality of food and drugs, and treating cancer, Merck always promotes opportunities to break new ground.